Postimplantation Syndrome
Conditions
Interventions
Experimental group:After TEVAR operation, loxoprofen sodium tablets 60mg were taken orally 3 times a day
Control group:Do not take loxoprofen sodium tablets after TEVAR surgery
Sponsors
General Hospital of Northern Theater Command
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged = 18 years 2. Aortic disease patients with planed elective TEVAR 3. Voluntarily sign informed consent and agree to receive study medication and clinical follow-up.
Exclusion criteria
Exclusion criteria: 1. Aged <18 years 2. Traumatic or infected aortic coarctation, Marfan syndrome, etc. 3. History of previous aortic surgery (e.g.Bentall operation) or previous TEVAR 4. History of surgery within the last month 5. History of autoimmune disease, systemic inflammation or malignancy 6. Use of anti-inflammatory drugs (including aspirin for coronary artery disease, etc.), immunosuppressive drugs, chemotherapeutic drugs, etc., or undergoing immunosuppressive therapy within 1 week prior to admission. 7. Suffering from chronic infectious diseases such as hepatitis A and B. 8. Disease progression (e.g. retrograde rupture of the graft into the ascending aorta) requiring surgical intervention. 9. Pregnancy 10. Allergic to loxoprofen sodium tablets. 11. Cann't tolerate Loxoprofen sodium tablets because of severe gastroduodenal disease. 12. Asthma, urticaria or allergic reaction caused by previous use of non-steroidal anti-inflammatory drugs. 13. Perioperative coronary artery bypass graft surgery. 14. Congestive heart failure 15. Severe haematological abnormalities 16. Severe liver or kidney impairment 17. No desire for TEVAR treatment or poor compliance with clinical trials 18. Failure to sign informed consent 19. Participation in other ongoing clinical trials that have not yet met their primary endpoints.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Postimplantation Syndrome; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imageological examination;Laboratory inspection items;Incidence of major cardiovascular events;Incidence of aortic adverse events;Safety index; | — |
Countries
China
Contacts
Public ContactWang Xiaozeng
General Hospital of Northern Theater Command
Outcome results
None listed